Emjard (Empagliflozin) is an oral prescription medicine containing empagliflozin, an SGLT2 (sodium-glucose co-transporter 2) inhibitor. It is used in the management of type 2 diabetes mellitus and is also used in appropriate adults with heart failure.
How does empagliflozin work?
Empagliflozin blocks the SGLT2 transporter in the proximal renal tubules.
This causes:
- Reduced reabsorption of filtered glucose.
- Increased glucose excretion through urine.
- Reduced blood glucose levels.
- Increased urinary sodium and water excretion.
The additional loss of glucose and sodium can also contribute to reductions in blood pressure and fluid volume, which is relevant to some patients with heart failure
USES / INDICATIONS
Emjard (empagliflozin) may be prescribed for:
- Type 2 diabetes mellitus to improve glycaemic control alongside diet and exercise
- Reduction of cardiovascular death in appropriate adults with type 2 diabetes and established cardiovascular disease
- Reduction of cardiovascular death and hospitalisation for heart failure in appropriate adults with heart failure
- Certain adults with chronic kidney disease at risk of progression, according to applicable prescribing guidance
PRECAUTIONS & WARNINGS
Tell your doctor if you have:
- Kidney disease or reduced kidney function
- Low blood pressure or a tendency to become dehydrated
- Recurrent urinary or genital infections
- A history of diabetic ketoacidosis
- Severe illness, vomiting or diarrhoea
- Upcoming major surgery or prolonged fasting
Seek urgent medical attention for symptoms suggestive of diabetic ketoacidosis, severe dehydration or a serious genital infection.
Use during pregnancy and breastfeeding should be discussed with a healthcare professional.
COMMON SIDE EFFECTS
Possible side effects include:
- Increased urination
- Increased thirst
- Genital fungal infections
- Urinary tract infections
- Dehydration
- Dizziness
- Low blood pressure
Seek urgent medical attention for severe weakness, vomiting, abdominal pain, difficulty breathing, confusion or other symptoms suggestive of diabetic ketoacidosis.
